{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-054475","form_type":"8-K","ticker":"TMCI","cik":"0001630627","company_name":"TREACE MEDICAL CONCEPTS, INC.","filed_at":"2024-05-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.326177+00:00","generated_at":"2026-06-02T18:43:05.815853+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.78,"calibrated_materiality_score":0.78,"confidence":"high","headline":"Treace Medical Q1 revenue $51.1M (+21% YoY), cuts FY2024 guidance to $201-$211M","bullets":["Q1 revenue $51.1M (+21% YoY); net loss $18.7M ($0.30/share) vs $13.5M loss in Q1 2023.","FY2024 revenue guidance slashed to $201-$211M from $220-$225M, citing increased MIS Osteotomy competition and knockoffs.","Adjusted EBITDA loss improved to $8.3M in Q1 from $10.0M in prior year.","CEO plans two new 3D MIS Osteotomy launches later in 2024 to counter competitive headwinds.","Cash and marketable securities $112.1M; 63 granted US patents as of March 31, 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-054475","json":"https://secwatch.observer/filing/0000950170-24-054475.json","markdown":"https://secwatch.observer/filing/0000950170-24-054475.md","text":"https://secwatch.observer/filing/0000950170-24-054475.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1630627/000095017024054475/0000950170-24-054475-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1630627/000095017024054475/tmci-20240507.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T18:43:05.815853+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d91be5a73b173841ec9182b7a7281d507dbd78e0","claim":"TREACE MEDICAL CONCEPTS, INC. reported the first quarter ended March 31, 2024 results: revenue $51.1 million, net income ($18.7) million, EPS ($0.30) per share. Guidance lowered.","evidence_excerpt":"through its flagship Lapiplasty ® and Adductoplasty ® Procedures, today reported financial results for the first quarter ended March 31, 2024. Recent Highlights • Revenue of $51.1 million in first quarter 2024 increased 21% over same period in 2023 • Gross margin of 80.2% in first quarter 2024 • First quarter 2024 net loss attributable to common stockholders was","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1630627/000095017024054475/0000950170-24-054475-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2024"},{"label":"Revenue","value":"$51.1 million"},{"label":"Net income","value":"($18.7) million"},{"label":"EPS","value":"($0.30) per share"},{"label":"Guidance","value":"lowered"},{"label":"Result","value":"reported results"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}